<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2207">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04686734</url>
  </required_header>
  <id_info>
    <org_study_id>LoTECA</org_study_id>
    <nct_id>NCT04686734</nct_id>
  </id_info>
  <brief_title>Long-term Effects of COVID-19 in Adolescents</brief_title>
  <acronym>LoTECA</acronym>
  <official_title>Long-term Effects of COVID-19 in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching objective for this prospective cohort study of COVID-19 in adolescents is to&#xD;
      study the long-term effects, with particular emphasis on post-infectious chronic fatigue. A&#xD;
      total of 500 individuals with a SARS-CoV-2 positive test will be enrolled in the acute phase&#xD;
      of COVID-19 and followed for 6 months. A total of 100 individuals with SARS-CoV-2 negative&#xD;
      test will be included during the same time period as a control group. Investigations include&#xD;
      autonomic, pulmonary and cognitive assessement; a questionnaire charting symptoms,&#xD;
      emotionality, personality, loneliness, life events and demographics; and extensive biobanking&#xD;
      including genetic markers, viable PBMC, urine, feces and hair. A subgroup of 40 SARS-CoV-2&#xD;
      positive and 20 SARS-CoV-2 negative individuals will also undergo detailed cardiological&#xD;
      examination by echocardiography. Primary endpoint is fatigue at 6 months as assessed by the&#xD;
      Chalder Fatigue Scale.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue</measure>
    <time_frame>6 months follow-up</time_frame>
    <description>Total sum score on the Chalder Fatigue Scale (range 0 - 33, lower scores means less fatigue, ie. better outcome)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>SARS-CoV-2 positive</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>SARS-CoV-2 negative</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No active intervention (observational only)</intervention_name>
    <description>No active intervention (observational only)</description>
    <arm_group_label>SARS-CoV-2 negative</arm_group_label>
    <arm_group_label>SARS-CoV-2 positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adolescents living in the counties of Oslo and Viken, Norway&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive SARS-CoV-2 test/negative SARS-CoV-2 test&#xD;
&#xD;
          -  Age 12 - 25 years&#xD;
&#xD;
          -  Living in the counties of Oslo or Viken, Norway&#xD;
&#xD;
          -  &lt; 28 days since onset of first symptom&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hospitalised due to COVID-19&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lack of consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vegard Wyller, PhD</last_name>
    <phone>91166681</phone>
    <phone_ext>+47</phone_ext>
    <email>v.b.b.wyller@medisin.uio.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vegard Bratholm Wyller</name>
      <address>
        <city>Oslo</city>
        <zip>1170</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vegard B Wyller, MD</last_name>
      <phone>+4791166681</phone>
      <email>v.b.b.wyller@medisin.uio.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>https://www.ahus.no/kliniske-studier/langtidseffekter-etter-koronavirusinfeksjon-covid-19-hos-ungdommer</url>
    <description>Information for patients and other public stakeholders</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 27, 2020</study_first_submitted>
  <study_first_submitted_qc>December 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Vegard Wyller</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 20, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT04686734/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 4, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT04686734/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

